Trial
NCT04249622
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
Anatomic Stage I Breast Cancer AJCC v8
Intervention
Best Practice
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16